Codeine and Rescheduling Hydrocodone Combination Products

Published Online: Tuesday, January 28, 2014
Follow Pharmacy_Times:
In this video, Jeff Fudin, PharmD, FCCP, adjunct associate professor at the Albany College of Pharmacy and adjunct assistant professor at the UCONN School of Pharmacy, argues that categorizing hydrocodone combination products as Schedule II could lead to increased prescription of codeine, a much “sloppier” drug that could create problems for patients.
 
This is the tenth in a series of videos in which Dr. Fudin argues against categorizing hydrocodone combination products as Schedule II drugs, and Mary Lynn McPherson, PharmD, argues in favor of doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)
 
These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
Chronic pain patients using prescription opioids in conjunction with medical marijuana are not at increased risk for substance abuse.
Despite advances in pain management and palliative care, intractable cancer pain remains a significant clinical, social, and financial burden in treating the oncologic population.
The FDA today approved a new cough and cold treatment that is also intended for adults with symptoms related to upper respiratory allergies.
Pharmacists are positioned to educate and monitor older patients who are discharged on these medications.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$